Introducere. 
with 6 series of Gemcitabine and Cisplatin with partial response, followed by Erlotinib treatment with favorable progression with regression of tumor size. hard to convince us to dig further into TKI toxicity. After finding out a few case reports (3, 4) from different type of patients which were considered to be potentially affected by erlotinib, we postulate that every each and one of this kind of events must be reported and seriously evaluated.
In December 2017, he presents recurrent episodes of atypical angina lasting about 2 weeks.

The electrocardiographic examination reveals ST segment elevation, with tall T waves and Q waves are present in the lower branches, associated with the increase of myocardial necrosis enzymes. Echocardiography highlights inferior hypokinesia with left ventricle ejection rate estimated at 45%. The patient has a favorable evolution during admission without recurrence of pain. Coronary angiography is performed at distance with evidence of vascular atherosclerotic lesions and the installation of active pharmacodynamic stents.
Discussions. Tyrosine kinase inhibitors may be the cause of acute coronary events both
We consider that cardiac toxicity caused by erlotinib treatment requires serious attention from the physicians, even though their adverse effects are less pronounced than other TKI. Caution and attentions must be paid when administering TKI, such as erlotinib, to patients with advanced neoplasia, particularly elderly patients or those with a history of coronary heart disease . We have to emphasize the fact (5) that a comprehensive assessment of the patients should be performed before starting t h e t r e a t m e n t , a n d a l s o t h a t E C G , echocardiography and myocardial enzymes testing must be performed at on a scheduled basis so that serious adverse reactions may be identified early in their progression and managed quickly.
